These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 14871843)

  • 1. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents.
    Simeoni M; Magni P; Cammia C; De Nicolao G; Croci V; Pesenti E; Germani M; Poggesi I; Rocchetti M
    Cancer Res; 2004 Feb; 64(3):1094-101. PubMed ID: 14871843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Terranova N; Germani M; Del Bene F; Magni P
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
    Friberg LE; Henningsson A; Maas H; Nguyen L; Karlsson MO
    J Clin Oncol; 2002 Dec; 20(24):4713-21. PubMed ID: 12488418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
    Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based approach to the in vitro evaluation of anticancer activity.
    Del Bene F; Germani M; De Nicolao G; Magni P; Re CE; Ballinari D; Rocchetti M
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):827-36. PubMed ID: 18663447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
    Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mathematical model to study the effects of drugs administration on tumor growth dynamics.
    Magni P; Simeoni M; Poggesi I; Rocchetti M; De Nicolao G
    Math Biosci; 2006 Apr; 200(2):127-51. PubMed ID: 16516246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
    Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
    Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
    Goteti K; Garner CE; Utley L; Dai J; Ashwell S; Moustakas DT; Gönen M; Schwartz GK; Kern SE; Zabludoff S; Brassil PJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):245-54. PubMed ID: 19841922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
    Cao S; Durrani FA; Rustum YM
    Clin Cancer Res; 2004 Apr; 10(7):2561-9. PubMed ID: 15073137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New analogues of camptothecins. Activity and resistance.
    Boven E; Van Hattum AH; Hoogsteen I; Schlüper HM; Pinedo HM
    Ann N Y Acad Sci; 2000; 922():175-7. PubMed ID: 11193892
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological determinants of 9-aminocamptothecin cytotoxicity.
    Li ML; Horn L; Firby PS; Moore MJ
    Clin Cancer Res; 2001 Jan; 7(1):168-74. PubMed ID: 11205905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.
    Mo G; Gibbons F; Schroeder P; Krzyzanski W
    PLoS One; 2014; 9(10):e109747. PubMed ID: 25333487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.
    Mangas-Sanjuan V; Buil-Bruna N; Garrido MJ; Soto E; Trocóniz IF
    J Pharmacol Exp Ther; 2015 Jul; 354(1):55-64. PubMed ID: 25948593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.